Log In
BCIQ
Print this Print this
 

DX-2930

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionHuman mAb against plasma kallikrein
Molecular Target Kallikrein
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$6,546.0M

$5,900.0M

$646.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/22/2016

$6,546.0M

$5,900.0M

$646.0M

Get a free BioCentury trial today